SB431542: Difference between revisions
Jump to navigation
Jump to search
imported>Kevin |
imported>Xenbase |
||
| Line 23: | Line 23: | ||
*[http://www.xenbase.org/literature/article.do?method=display&articleId=371 Ho et al., 2006] | *[http://www.xenbase.org/literature/article.do?method=display&articleId=371 Ho et al., 2006] | ||
*[http://www.xenbase.org/literature/article.do?method=display&articleId=49634 Chiu 2014] | *[http://www.xenbase.org/literature/article.do?method=display&articleId=49634 Chiu 2014] | ||
*[http://www.xenbase.org/literature/article.do?method=display&articleId=54570 Sato et al 2018] | |||
*[https://pubchem.ncbi.nlm.nih.gov/ Pubchem] | *[https://pubchem.ncbi.nlm.nih.gov/ Pubchem] | ||
Revision as of 12:16, 9 April 2018
Description
"Potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-β-induced proliferation of human osteosarcoma cells. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells."
- -Tocris Product Description
Genes Affected
Suppliers
Usage Notes
References
>23 Xenbase articles contain a reference to SB-431542 according to textpresso